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ABSTRACT 
 
Tachycardia mediated cardiomyopathy (TMC) is a reversible form of dilated cardiomyopathy 
that can occur with most supraventricular and ventricular arrhythmias. Despite the plethora of 
literature describing this entity in animal models, as well as humans, it remains poorly 
understood. Over the last decade, new etiologies of TMC, such as frequent premature ventricular 
complexes in normal hearts, have been identified.  Recent advances in catheter-based ablation 
therapies, particularly for atrial fibrillation and ventricular arrhythmias, have added a new 
dimension to the treatment of this condition. This review describes the pathophysiology, 
proposed mechanisms, clinical features and management in various arrhythmic conditions.   
 
KEY WORDS: tachycardia mediated cardiomyopathy, tachycardia-induced heart failure, 
tachyarrhythmias 
 
INTRODUCTION 
Incessant tachyarrhythmias can lead to ventricular dilation and systolic dysfunction with signs 
and symptoms of heart failure (HF). Tachycardia-induced HF was first described in 1913 in a 
patient with atrial fibrillation (1). Philips and Levine described the relationship between rapid 
atrial fibrillation and reversible heart failure in 1949 (2). Whipple and colleagues developed an 
experimental model of tachycardia-mediated cardiomyopathy (TMC) in 1962 (3). Fenelon and 
colleagues divided TMC in to two types: 1. pure, where tachycardia is the sole mechanism of 
worsening of LV function; and 2. impure, where tachycardia worsens a pre-existing 
cardiomyopathy due to a different cause (4).  
 
Over the last 3 decades, multiple papers have described this entity in both animal models and in 
humans. Despite the plethora of literature, TMC remains a poorly understood entity. This review 
describes the pathophysiology, clinical features and natural history of TMC. 
 
PATHOPHYSIOLOGY AND PROPOSED MECHANISMS 
 
SYSTOLIC FUNCTION: In animal models of pacing-induced HF, sustained atrial or ventricular 
pacing produce severe biventricular systolic dysfunction. This is characterized by increased 
ventricular filling pressures, decreased cardiac output and increased systemic vascular resistance, 
without a change in left ventricular (LV) mass (5,6,7). There is loss of intrinsic myocardial 
contractility with diminished contractile reserve.  The marked dilation of ventricles is 
accompanied by lack of hypertrophy of the left ventricular wall. Microscopic alterations include 
myocyte loss, myocyte elongation, and effacement of the interface between the basement 
membrane and sarcolemmal surface.  The latter leads to decrease force transmission through the 
ventricular wall (8,9).  Depletion of T-tubules occurs in failing ventricular myocytes with rapid 
pacing, with associated decreases in the density of L-type calcium channels and beta-adrenergic 
receptors in both surface and T-tubular sarcolemmata. This heterogeneous loss of T-tubules 
results in abnormal excitation-contraction coupling and may impair contractile efficiency by 
causing variability in time course of activation of cells (10).  
 
DIASTOLIC FUNCTION: Tachycardia also affects diastolic function by causing incomplete 
relaxation whereby the myocardium remains in a constant activated state that can be described as 
a partial or diastolic contracture (11).  Calcium extrusion from cardiomyocytes occurs mainly by 
the sarcolemmal sodium-calcium exchanger. In concert with the sarcoplasmic reticulum (SR), 
the exchanger restores cytosolic calcium to diastolic levels, thereby causing relaxation. With 
tachycardia, there is a disproportionate increase in SR calcium content, causing extrusion of 
calcium in a high calcium environment, which manifests as diastolic contracture (12). 
 
HIGH ENERGY PHOSPHATES: TMC causes depletion of high energy stores in the 
myocardium due to increased metabolism from persistent tachycardia; this being a reversible 
process.  Tissue adenosine triphosphate (ATP), as well as sodium-potassium ATPase, are 
significantly decreased in animals with pacing-induced HF (13, 14), while there is an increase in 
beta-oxidation enzymes and enzymes involved in the Krebs’ cycle (15). Selective endothelin-
receptor blockade has been shown to attenuate progression of HF by reversing mitochondrial 
dysfunction (specifically by affecting levels of respiratory complexes V and III involved in the 
Krebs’ cycle) in animal models of TMC, thus suggesting the role of endothelin activation in 
causing ventricular dysfunction (16). 
 
MYOCARDIAL BLOOD FLOW: Chronic supraventricular tachycardia (SVT) in animals has 
also been shown to result in decreased myocardial blood flow, which normalizes after pacing is 
terminated (17,18).  This may be due to marked elevation of LV end-diastolic pressure (19). 
 
OXIDATIVE STRESS: Oxidative stress has been proposed as a mechanism contributing to 
TMC in patients with atrial fibrillation (AF). In AF, oxidative modification of ventricular 
myofibrillar proteins occurs due to peroxynitrite formation, leading to loss of fibrillar function, 
eventually causing contractile dysfunction (20,21). In an animal study of pacing-induced HF, 
antioxidant vitamins reduced myocardial oxidative stress, attenuated cardiac dysfunction and 
prevented myocardial beta-receptor down-regulation and sympathetic nerve terminal dysfunction 
(22). 
 
ANGIOTENSIN CONVERTING ENZYME: Angiotensin-converting enzyme (ACE) 
polymorphisms have also been implicated in TMC. Patients with DD genotype (287 base pair 
deletion in intron 16 of the ACE gene) show exaggerated ACE production in response to any 
stimulus such as incessant tachycardia.  The resultant increase in levels of angiotensin-II causes 
myocyte elongation, left ventricular enlargement and changes in wall stress (23, 24). 
 
NEUROHORMONAL CHANGES: The neurohumoral changes seen in TMC are similar to those 
in other forms of HF and occur in response to a depressed cardiac output. Activation of the renin-
angiotensin-aldosterone axis occurs with elevated levels of angiotensin-II, atrial natriuretic 
peptide (ANP) and endothelin-1, causing abnormal sodium handling. In pacing-induced HF, 
changes in heart rate, atrial pressure and volume cause increased plasma ANP concentrations, 
which are attenuated by 1 week due to inability of the atria to be stretched further and because of 
depletion of atrial ANP concentrations (25, 26). As in other disease states, elevated levels of 
aldosterone may lead to myocardial fibrosis (27, 28). 
 
BETA-ADRENERGIC RECEPTORS: There is blunted response to beta-adrenergic stimulation 
in TMC due to decreased expression of beta-receptors, alterations in beta-receptor transduction 
including decreased G stimulator protein density (Gs), increased G inhibitory protein density 
(Gi), and reduced adenylate cyclase activity (29,30,31). 
 
MITRAL REGURGITATION: Similar to other forms of dilated cardiomyopathy, patients with 
TMC can develop mitral regurgitation (MR) due to mitral annular dilatation and separation of the 
leaflet hinge points, causing incomplete leaflet coaptation and valve incompetence (32). The 
saddle shaped mitral annulus in TMC dilates more in the septal-lateral than in the commissure-
commissure dimension with flattening of the annulus and decreased contraction occurring in the 
lateral annulus (33). There is also lengthening of the mitral leaflets due to remodeling near the 
leaflet edges (34). 
 
RIGHT VENTRICLE: The right ventricle (RV) responds somewhat differently to tachycardia. 
Unlike the LV where chamber dilation occurs without increase in mass, in the RV, both chamber 
and myocyte hypertrophy develop. These changes in RV myocardial geometry are associated 
with persistently higher RV myocyte contractile function compared to LV myocytes in TMC 
(35). 
 
RECOVERY FROM TMC: In animal studies, recovery from TMC is associated with a 
hypertrophic response of the left ventricle with persistent dilation despite normalization of 
systolic function (17). This has subsequently been confirmed in clinical studies (36). Diastolic 
dysfunction can persist even after normalization of systolic function (37). Myocardial blood flow 
returns to normal, but with decreased coronary flow reserve. Therefore, episodic increases in 
myocardial oxygen demand in post-supraventricular tachycardia hearts (e.g., with recurrence of 
tachycardia) can result in reduced myocardial blood flow and reduced LV function (17). 
 
In a study comparing patients with TMC due to SVT with those with idiopathic dilated 
cardiomyopathy (DCMP), significant improvement in LV ejection fraction was noted in the 
former group with rate control. LV dimensions and mass and volume indices were smaller in the 
TMC group than DCMP group. A lower LV end-diastolic dimension was the only significant 
predictor of recovery in multivariable analysis (38). 
 
In a recent study of 18 patients with TMC due to focal atrial tachycardia that had an 
improvement in ejection fraction within 3 months of radiofrequency ablation, subtle differences 
in LV structure and function were noted at 5 years, with larger LV dimensions, lower EF, 
decreased myocardial strain and twist rate and evidence of diffuse myocardial fibrosis on late 
gadolinium enhanced cardiac MRI, suggesting incomplete recovery (39).  
 
TACHYCARDIA-MEDIATED ATRIAL CARDIOMYOPATHY (TMAC) 
Atrial tachycardia and atrial fibrillation (AF) have been shown to cause contractile dysfunction 
of the atria. In addition, cardioversion of AF to sinus rhythm causes atrial mechanical 
dysfunction, the degree of which depends upon the duration of preceding AF (40, 41). Rapid 
atrial pacing affects both atrial systolic and diastolic function characterized by absent atrial 
booster pump function, increased atrial chamber stiffness, enhanced atrial conduit function, and 
atrial enlargement (42). Abnormalities in calcium handling and impaired systolic transient 
calcium currents due to downregulation or dysfunction of the L-type calcium channel and altered 
myofilament function (associated with abnormal myosin and myosin-associated protein 
phosphorylation) have been proposed as mechanisms of the atrial cardiomyopathy (43,44,45,46). 
Upregulation of the sodium-calcium exchanger worsens calcium depletion by causing its efflux 
from atrial cardiomyocytes of AF patients, thus contributing to the atrial contractile dysfunction 
post cardioversion. Unlike its ventricular counterpart, beta-adrenergic receptor desentization 
does not contribute to TMAC (47). 
 
INCIDENCE AND PREDISPOSING FACTORS 
The incidence of TCM is variable depending upon the type of tachycardia. In a study of 625 
patients referred for radiofrequency ablation of tachyarrhythmias, TCM was found in 17 patients 
(2.7%) (48). The incidence for specific arrhythmias has been described as ranging from 10% in 
patients with focal atrial tachycardia (49), to 20-50% in patients with permanent junctional 
reciprocating tachycardia (PJRT) (50, 51) and  25% in patients with incessant atrial flutter (52).  
The incidence of TCM in atrial fibrillation and ventricular tachycardia has not been described 
adequately in literature. Younger patients, males, those with slower tachycardias, and incessant 
tachycardias are more prone to develop TMC according to one study (49). Those with rapid 
paroxysmal tachycardias are more likely to be symptomatic and be diagnosed sooner than those 
with slower, but incessant tachycardias In patients with atrial fibrillation (AF), the irregularity of 
R-R interval may itself predispose to cardiomyopathy and heart failure, apart from the effects of 
rapid heart rates (50).  
 
DIAGNOSIS AND MANAGEMENT 
There are no established diagnostic criteria for TMC. However, in a patient presenting with new 
onset LV dysfunction and a chronic or recurrent tachycardia with heart rate over 100 beats per 
minute, the diagnosis of TMC may be suggested by the following once ischemic cardiomyopathy 
is ruled out: 
1. No other cause of non-ischemic cardiomyopathy found (eg. hypertension, alcohol or drug 
use, stress etc.) 
2. Absence of LVH 
3. Relatively normal LV dimensions (LV end-diastolic dimension< 5.5 cm) 
4. Recovery of LV function after control of tachycardia (by rate control, cardioversion or 
radiofrequency ablation) within one to six months. 
5. Rapid decline in LVEF following recurrence of tachycardia in a patient with recovered 
LV function after control of tachycardia previously. 
In addition, there is evidence that the ratio of N-terminal-pro brain natriuretic peptide (NT-pro-
BNP) concentration in patients with suspected TMC before and after control of tachycardia may 
help in distinguishing these patients from those with structural heart disease. In one study, the 
level of NT-pro-BNP was elevated in patients with SVT with depressed LV function and 
declined after cardioversion within a week (51). Thus serial measurements of NT-pro-BNP may 
be useful in supportive diagnosis of TMC, though this requires further exploration.  
Initial management of TMC comprises evidence-based treatment for HF with reduced LVEF, 
including angiotensin converting enzyme inhibitors and beta-blockers. Treatment of tachycardia 
involves control of ventricular response with rate-controlling drugs, use of anti-arrhythmic drugs, 
direct-current cardioversion or catheter ablation of the tachyarrhythmia.  
 
 TMC AND RECURRENT TACHYCARDIA 
TMC usually resolves with treatment of tachycardia. The time course of improvement in LVEF 
is variable. However, recurrence of tachycardia can cause a precipitous decline in LVEF due to 
persistent ultrastructural changes. Nerheim et al (52) described a series of 24 patients with TMC 
out of which 5 had recurrent tachycardia causing marked decline in LVEF. Three of their 
patients died suddenly and unexpectedly. This suggests that patients may be at increased risk for 
sudden cardiac death following improvement of TMC, which could be due to persistent 
myocardial fibrosis as demonstrated on cardiac MR (39).  
 
ARRHYTHMIAS ASSOCIATED WITH TMC 
A list of tachyarrhythmias that have been associated with TMC is shown in Table 1. Both 
supraventricular and ventricular arrhythmias can cause TMC, as can sinus tachycardia, 
particularly in association with thyrotoxicosis. We present some common arrhythmias associated 
with TMC and salient features in their management. 
 
ATRIAL FIBRILLATION (AF): AF is the most common sustained arrhythmia, encountered in 
1.5% of the population (53). AF compromises LV systolic function through poor rate control 
(usually sustained ventricular rates above 120 beats per minute), irregularity of ventricular 
response, and loss of atrial systolic activity. Loss of atrioventricular (AV) synchrony is 
associated with impaired diastolic filling, reduced stroke volume, and elevated diastolic atrial 
pressure, resulting in an approximately 20% reduction in cardiac output (54). AF and HF thus 
form a vicious cycle whereby one worsens the other.  
 
Although conversion of a patient back to sinus rhythm appears an attractive therapeutic goal, in 
both AFFIRM (AF Follow-Up Investigation of Rhythm Management) and RACE (Rate Control 
Versus Electrical Cardioversion for Persistent AF) trials, rhythm control strategy provided no 
benefit and actually showed a trend toward harm in the general population of patients compared 
with rate control (55, 56). This was due, at least in part, to toxicity of the anti-arrhythmic drugs, 
along with an inability to maintain SR in most patients. These trials, however, did not address the 
issue of TMC.  
 
Although rate control was found to be superior to rhythm control in AFFIRM and RACE, 
subsequent analyses suggested a benefit of maintaining sinus rhythm, which was completely 
offset by the toxicity of anti-arrhythmic drugs (57,58). One technique of achieving sinus rhythm 
without anti-arrhythmic drugs would be curative catheter ablation. In most cases, 
paroxysmal AF is initiated by triggers located within pulmonary vein musculature. 
Circumferential ablation to isolate this musculature can eliminate paroxysmal AF in selected 
populations. Because of the problem of recurrent pulmonary vein connections, more than one 
procedure is needed in approximately 30% of patients, and new technologies are being 
developed to reduce this requirement (59). In a study of patients undergoing pulmonary vein 
isolation, 18% had depressed LVEF (<50%). The mean LVEF improved significantly in these 
patients following ablation, the improvement being more marked in those who achieved 
successful AF control (Figure 1). Of note, the degree of AF control in these patients was similar 
to that in patients with normal LV function, but they required more procedures (60).   
 
The Pulmonary Vein Antrum Isolation versus AV Node Ablation with Bi-Ventricular Pacing for 
Treatment of Atrial Fibrillation in Patients with Congestive Heart Failure (PABA-CHF) study 
was a multicenter, randomized, controlled trial comparing pulmonary vein isolation with 
atrioventricular-node biventricular pacing in patients with symptomatic AF, NYHA class II or III 
HF and LVEF ≤ 40% (61). Patients who underwent pulmonary vein isolation demonstrated 
greater improvement in LVEF, six-minute walk distance and quality of life parameters at 6 
months compared to the latter group.  However, long term superiority of one strategy over the 
other has not been established as this was a relatively short follow-up period.  
 
Catheter ablation is now being explored as first line therapy in persistent AF. A recent 
randomized, open label, blinded-endpoint clinical trial involving 52 patients with symptomatic 
HF, persistent AF and LVEF ≤ 35%, compared catheter ablation with rate control (62). Catheter 
ablation significantly improved peak oxygen consumption (VO2), Minnesota Living with Heart 
Failure Questionnaire score and brain-natriuretic peptide (BNP) values at 12 months, with a 
trend towards increase in LVEF and six-minute walk distance. In this study, 96% of patients in 
the rate control group had adequate rate control at 12 months, and maintenance of SR was 
achieved in 92% of patients in ablation group. This study suggests that rhythm control with 
successful ablation of AF may have an overall advantage over adequate rate control for 
physiologic improvement, though longer follow-up is necessary. 
 
An extreme form of rate control strategy is atrioventricular (AV) nodal ablation with 
implantation of a permanent pacemaker, the “ablate and pace strategy” . This procedure’s use is 
reserved largely for older patients with significant co-morbidities. It does result in progression of 
paroxysmal AF to permanent AF in up to 32% of patients within 2 months. Also, continuous 
right ventricular pacing itself has deletrious effects on LV systolic function due to LV 
dyssynchrony (63). However, AV nodal ablation may be beneficial if simultaneous cardiac 
resynchronization therapy (CRT) is performed in patients meeting CRT criteria.  In a systematic 
review of 3 studies, AV nodal ablation was associated with a substantial reduction in all-cause 
mortality and cardiovascular mortality, with improvements in New York Heart Association 
functional class when compared with medical therapy in AF patients receiving CRT (64). 
 
TMC RELATED TO OTHER SUPRAVENTRICULAR ARRHYTHMIAS: TMC can develop 
with any form of frequent paroxysmal or incessant supraventricular tachycardia. Patients with 
chronic atrial flutter have been shown to develop TMC, which improves after radiofrequency 
ablation (65,66). In a study of 345 patients undergoing catheter ablation for focal atrial 
tachycardia, TMC was seen in 10% of cases (49). Patients with TMC were younger, more often 
male, had mostly incessant tachycardia, and had a longer tachycardia cycle length and slower 
ventricular rate compared to those who did not have TMC. Foci of atrial tachycardia were mostly 
found either in the atrial appendages or the pulmonary veins in patients with TMC.  
Normalization of LVEF was seen in 97% of patients at a mean follow-up of 3 months. Cruz et al. 
(67) described TMC resulting from incessant tachycardia due to an accessory pathway with a 
long retrograde conduction time, which was reversible following surgical ablation of the 
accessory pathway. Children may develop TMC with ectopic atrial tachycardia or permanent 
junctional reciprocating tachycardia, which is reversible following radiofrequency ablation 
(68,69,70,71).  
 
TMC RELATED TO VENTRICULAR ARRHYTHMIAS: Ventricular arrhythmias that can 
cause TMC include ventricular tachycardia (VT) in patients with structurally normal hearts and 
frequent, monomorphic premature ventricular contractions (PVC) (72). Multiple case reports and 
case series have described TMC in association with idiopathic right ventricular outflow tract VT 
(RVOT-VT) (73,74) and idiopathic left ventricular tachycardia (75), where the cardiomyopathy 
was reversible after successful radiofrequency ablation. In a study of 249 patients with idiopathic 
repetitive monomorphic PVCs and/or VT, 9% had TMC, and 29% of these were asymptomatic 
(76). All patients had improvement in LVEF following treatment with either anti-arrhythmics or 
radiofrequency ablation. The predictors for development of TMC identified were male gender, 
absence of symptoms, PVC burden of ≥16%, persistence of PVCs throughout the day, and the 
presence of repetitive monomorphic VT. In another study by the same group, late gadolinium 
enhancement on cardiac magnetic resonance imaging was seen in patients with TMC who did 
not recover their LV systolic function after treatment of the index VT (77). Late gadolinium 
enhancement on cardiac magnetic resonance imaging is indicative of scar, thus these patients 
probably did not have pure TMC.  
 
PVCs have been detected in 1% of subjects on standard 12-lead electrocardiography and 
between 40 and 75% of subjects on 24 to 48 hour ambulatory electrocardiographic monitoring in 
the normal population (78). PVCs were thought to be benign. However, in the last decade, 
cardiomyopathy due to frequent PVCs in otherwise healthy hearts is now recognized. In the 
Atherosclerosis Risk in Communities (ARIC) study, association of frequent PVCs with HF 
incidence in a population-based cohort, free of HF and coronary heart disease at baseline, was 
studied (79). Over a follow-up period of 15 years, the incidence of HF in subjects with >1 PVC 
on a 2 minute electrocardiographic rhythm strip was significantly higher than in those with no 
PVCs (hazard ratio 1.71, after adjusting for variables including coronary artery disease) (Figure 
2).  
 
The concept of PVC-induced cardiomyopathy was described by Duffee et al. (80) who noted that 
pharmacological suppression of PVCs in patients with presumed idiopathic dilated 
cardiomyopathy improved LV systolic dysfunction. The frequency of PVCs appears to correlate 
with LV dysfunction. Frequent PVCs have been variably defined as >10,000 PVCs in 24 hours 
(81), >20,000 PVCs in 24 hours (82) or >24% of total heart beats (83).  Approximately a third of 
patients with frequent PVCs develop cardiomyopathy. Two-thirds of PVCs arise from outflow 
tracts, particularly the RVOT, and one-third have various ventricular origins: free walls, LV 
fascicles, septum and papillary muscles.  
 
Mechanisms postulated for PVC-induced TMC include a true rate-related cardiomyopathy due to 
higher average heart rates in patients with frequent PVCs with a short coupling interval, LV 
dyssynchrony during PVCs and chronic effects of extra-systolic potentiation leading to increases 
in intracellular calcium and myocardial oxygen consumption (84). Ventricular dyssynchrony 
causes reduced global cardiac mechanical efficiency, asymmetrically increased wall thickness in 
the late-activated regions, altered myocardial blood flow, and local changes in myocardial 
protein expression, thus causing LV dilation and dysfunction in a manner similar to chronic RV 
pacing (85).  Identified predictors of cardiomyopathy in patients with frequent PVCs include 
(besides PVC burden) wider PVCs, PVCs of epicardial origin (86), presence of interpolated 
PVCs (87) and presence of retrograde P waves (88). The threshold burden of PVCs associated 
with reduced LVEF may be lower for right as compared to left ventricular PVCs (89). 
 
A therapeutic medical trial for 3 months or catheter ablation should be considered for patients 
with presumed PVC-induced cardiomyopathy. Beta-blockers, amiodarone and dofetilide can all 
suppress PVCs and can be safely used in patients with LV dysfunction (90,91,92). Catheter 
ablation has emerged as an increasing popular option for these patients as the safety and efficacy 
profiles of the procedure have improved. Several studies have documented an improvement in 
LVEF following PVC ablation in nearly all patients along with significant reductions in LV end-
diastolic dimensions of between 2 and 8 mm, mitral regurgitation by 75%, and New York Heart 
Association functional class by nearly 1 class (93,94,95). Significant improvement in radial, 
circumferential, and longitudinal strain after catheter ablation in patients with frequent PVCs and 
preserved LVEF has also been shown (96). Short-term ablation success rates of between 70% 
and 90% have been reported (97,98). Early improvement in LVEF after ablation (>25% increase 
at 1 week) was shown to predict complete recovery of LV systolic function in one study (98).  
 
TMC IN THYROTOXICOSIS: Approximately 6% of patients with thyrotoxicosis develop HF 
symptoms, but only 1% develop dilated cardiomyopathy with reduced LV systolic function. This 
can occur with sinus tachycardia or atrial fibrillation with a rapid ventricular response. HF 
resulting from thyrotoxicosis is due to a tachycardia-mediated mechanism leading to increased 
levels of cytosolic calcium during diastole with reduced ventricular contractility and diastolic 
dysfunction (99). Most patients recover their LV systolic function after control of tachycardia 
and achievement of a euthyroid state. Patients who develop TMC have lower levels of serum 
thyroxine than those who do not, which reflects a higher incidence of subclinical 
hyperthyroidism in these patients (100).  
 
FUTURE DIRECTIONS 
While there is an abundance of animal studies on TMC, studies in humans are remarkably 
limited. Future research needs to be directed towards studying the pathophysiology of this entity 
in human beings, with particular reference to predisposing factors. It is likely that genetic factors 
(such as ACE polymorphism which has already been described) will be found to play a 
significant role in the development of TMC.  Emerging data suggest that the presence of fibrosis 
on cardiac MR imaging may identify patients with TMC who are less likely to recover their LV 
function. These patients may be at elevated risk of recurrence of TMC as well as sudden cardiac 
death, which is a hypothesis that needs further exploration. In addition, with reference to atrial 
fibrillation, it remains to be determined whether conversion to sinus rhythm with catheter 
ablation has long-term superiority over rate control strategy in certain patients with TMC.  
 
 
 CONCLUSIONS 
TMC is a form of dilated cardiomyopathy which can be reversible with treatment of the 
underlying tachycardia. TMC patients who gain return of LV function do remain at an elevated 
risk for recurrence and for sudden cardiac death, hence long-term follow-up of these patients is 
necessary.  
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FIGURE LEGENDS 
 
1. Improvement in left ventricular ejection fraction (LVEF) based on atrial fibrillation (AF) 
control with ablation in patients with low LVEF. Improvement in LVEF was greater in those 
patients with AF control after ablation than in those with recurrent AF (P< 0.01).  
Reprinted with permission from:  Marchlinski FE, Journal of Cardiovascular Electrophysiology 
Volume 18, Issue 1, pages 9-14, January 2007. 
2. Multivariable adjusted cumulative heart failure events during follow up by the presence 
any VPCs (143 HF events among 739) vs. absence (1201 HF events among 12747) events in a 
2-minute ECG strip among ARIC cohort participants free of heart failure and coronary heart 
disease at study baseline. (Wilcoxon test P<0.001). Model adjusted for age, gender, race, 
study center, education level, diabetes, systolic blood pressure, hypertension medication 
intake, LDL and HDL cholesterol, BMI, current smoking, former smoking, pack-years of 
smoking, amount of ethanol use, heart rate, serum K+, serum Mg++.  
Reprinted with permission from: Agarwal SK, American Journal of Cardiology Volume 109, 
Issue 1, pages 105-109, January 2012.  
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Figure 2 
 
Table 1. Types of Arrhythmias Causing Tachycardia-Mediated Cardiomyopathy 
 
Supraventricular 
 Atrial fibrillation 
 Atrial flutter 
 Atrial tachycardia 
 Permanent junctional reciprocating tachycardia 
 AV nodal reentrant tachycardia 
 AV reentrant tachycardia 
 Inappropriate sinus tachycardia (rare cause) 
Ventricular 
 Right ventricular outflow tract ventricular tachycardia 
 Fascicular tachycardia  
 Bundle branch reentry ventricular tachycardia 
Ectopy 
 Premature ventricular complexes 
Pacing 
 Persistent rapid ventricular pacing 
 High-rate atrial pacing 
Other 
 Thyrotoxicosis (sinus tachycardia or atrial fibrillation) 
 
 
 
